{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:03:38Z","timestamp":1790021018553,"version":"4.0.1"},"reference-count":319,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ebm-journal.org"],"crossmark-restriction":true},"short-container-title":["Exp. Biol. Med."],"abstract":"<jats:p>Messenger RNA (mRNA) therapeutics have significantly transformed contemporary medicine, particularly through their role as the active component in the SARS-CoV-2 vaccine. This remarkable achievement is the culmination of extensive research conducted over many years by scientists. The widespread administration of the COVID-19 vaccine has further accelerated research into the precise therapeutic potential of mRNA technologies. Since mRNA doesn\u2019t integrate with the host genome, the safety and versatility of mRNA-based therapeutics make them an iconic candidate in targeted therapies. Due to a surge in innovation efforts, biomodification of the molecular signatures of mRNAs like the 5\u2032cap, untranslated regions (UTRs), and the poly(A) tail are being developed to increase translation efficacy. Recent advancements in chemical modifications, codon optimization techniques, and targeted delivery methods have significantly enhanced the stability of synthetic mRNAs while concurrently reducing their immunogenicity. Various mRNA manufacturing and synthesizing methods are investigated in this review, focusing on their scalability and limitations. mRNA therapeutic strategies can be divided into protein replacement, immune modulation, and cellular modulation. This review explores mRNA\u2019s molecular landscape and comprehensive utility, including applications in both clinical trials and commercial sectors.<\/jats:p>","DOI":"10.3389\/ebm.2025.10784","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:28:08Z","timestamp":1767864488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications"],"prefix":"10.3389","volume":"250","author":[{"given":"Saumya Nishanga","family":"Heendeniya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qurat Ul Ain","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Rahimizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal Hari","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh N.","family":"Veedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat Nanotechnology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e114760","DOI":"10.15252\/embj.2023114760","article-title":"RNA-based medicine: from molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"The EMBO J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/biomedicines10010050","article-title":"mRNA therapeutic modalities design, formulation and manufacturing under pharma 4.0 principles","volume":"10","author":"Ouranidis","year":"2021","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature11233","article-title":"Landscape of transcription in human cells","volume":"489","author":"Djebali","year":"2012","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11033-019-05230-7","article-title":"RNA: interactions drive functionalities","volume":"47","author":"Dai","year":"2020","journal-title":"Mol Biol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"113930","DOI":"10.1016\/j.addr.2021.113930","article-title":"Advances in mRNA non-viral delivery approaches","volume":"177","author":"Ibba","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"B11","doi-asserted-by":"publisher","first-page":"901510","DOI":"10.3389\/fcell.2022.901510","article-title":"The pivotal role of chemical modifications in mRNA therapeutics","volume":"10","author":"Liu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/pharmaceutics15010166","article-title":"mRNA in the context of protein replacement therapy","volume":"15","author":"Vavilis","year":"2023","journal-title":"Pharmaceutics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41589-023-01498-w","article-title":"Medicine from modified mRNA","volume":"19","author":"Johnson","year":"2023","journal-title":"Nat Chem Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B15","unstructured":"Coronavirus pandemic (COVID-19): ourworldindata.org\n          \n          \n            \n              Ritchie\n              H\n            \n            \n              Mathieu\n              E\n            \n            \n              Rod\u00e9s-Guirao\n              L\n            \n            \n              Appel\n              C\n            \n            \n              Giattino\n              C\n            \n            \n              Ortiz-Ospina\n              E\n            \n          \n          \n          2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"106780","DOI":"10.1016\/j.bpc.2022.106780","article-title":"Chemical modifications to mRNA nucleobases impact translation elongation and termination","volume":"285","author":"Franco","year":"2022","journal-title":"Biophysical Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.3390\/pharmaceutics13122090","article-title":"mRNA, a revolution in biomedicine","volume":"13","author":"Baptista","year":"2021","journal-title":"Pharmaceutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol Cell Toxicol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.1007\/s12274-024-6978-6","article-title":"mRNA medicine: recent progresses in chemical modification, design, and engineering","volume":"17","author":"Hou","year":"2024","journal-title":"Nano Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development","volume":"10","author":"Karik\u00f3","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"key":"B22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J Controlled Release"},{"key":"B23","doi-asserted-by":"publisher","first-page":"789427","DOI":"10.3389\/fcell.2021.789427","article-title":"The critical contribution of pseudouridine to mRNA COVID-19 vaccines","volume":"9","author":"Morais","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1016\/j.cell.2025.05.032","article-title":"Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagement","volume":"188","author":"B\u00e9routi","year":"2025","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1134\/s0006297921080083","article-title":"A code within a code: how codons fine-tune protein folding in the cell","volume":"86","author":"Komar","year":"2021","journal-title":"Biochemistry (Mosc)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40259-018-0261-x","article-title":"Codon optimization in the production of recombinant biotherapeutics: potential risks and considerations","volume":"32","author":"Mauro","year":"2018","journal-title":"BioDrugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrm.2017.91","article-title":"Codon optimality, bias and usage in translation and mRNA decay","volume":"19","author":"Hanson","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1126\/science.adm8143","article-title":"Rare codon recoding for efficient noncanonical amino acid incorporation in mammalian cells","volume":"384","author":"Ding","year":"2024","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","article-title":"Codon optimality is a major determinant of mRNA stability","volume":"160","author":"Presnyak","year":"2015","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1261\/rna.058180.116","article-title":"Codon optimality controls differential mRNA translation during amino acid starvation","volume":"22","author":"Saikia","year":"2016","journal-title":"Rna"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1000548","DOI":"10.1371\/journal.pgen.1000548","article-title":"Clustering of codons with rare cognate tRNAs in human genes suggests an extra level of expression regulation","volume":"5","author":"Parmley","year":"2009","journal-title":"PLoS Genet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"20608","DOI":"10.1038\/srep20608","article-title":"An engineered rare codon device for optimization of Metabolic pathways","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12126","DOI":"10.1038\/s41598-022-15526-7","article-title":"iCodon customizes gene expression based on the codon composition","volume":"12","author":"Diez","year":"2022","journal-title":"Scientific Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2205445","DOI":"10.1002\/advs.202205445","article-title":"Optimization and deoptimization of codons in SARS-CoV-2 and related implications for vaccine development","volume":"10","author":"Wu","year":"2023","journal-title":"Adv Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/c6sc02437h","article-title":"A novel route for preparing 5' cap mimics and capped RNAs: phosphate-modified cap analogues obtained via click chemistry","volume":"8","author":"Walczak","year":"2017","journal-title":"Chem Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1471-2105-8-s6-s2","article-title":"Transcriptional regulation at a glance","volume":"8","author":"Sperling","year":"2007","journal-title":"BMC Bioinformatics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/wrna.52","article-title":"Cap and cap-binding proteins in the control of gene expression","volume":"2","author":"Topisirovic","year":"2011","journal-title":"WIREs RNA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1099\/vir.0.80755-0","article-title":"Recognition of mRNA cap structures by viral and cellular proteins","volume":"86","author":"Fechter","year":"2005","journal-title":"J Gen Virol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41586-022-05668-z","article-title":"mRNA ageing shapes the Cap2 methylome in mammalian mRNA","volume":"614","author":"Despic","year":"2023","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10788","DOI":"10.1093\/nar\/gkae763","article-title":"Trinucleotide cap analogs with triphosphate chain modifications: synthesis, properties, and evaluation as mRNA capping reagents","volume":"52","author":"Warminski","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.3762\/bjoc.13.274","article-title":"Synthetic mRNA capping","volume":"13","author":"Muttach","year":"2017","journal-title":"Beilstein J Org Chem"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1002\/cpz1.39","article-title":"Cap 1 messenger RNA synthesis with Co-transcriptional CleanCap\u00ae analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","journal-title":"Curr Protoc"},{"key":"B46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1261\/rna.079460.122","article-title":"N2 modified dinucleotide cap analogs as a potent tool for mRNA engineering","volume":"29","author":"Grzela","year":"2023","journal-title":"Rna"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e202200005","DOI":"10.1002\/tcr.202200005","article-title":"Recent advances in modified cap analogs: synthesis, biochemical properties, and mRNA based vaccines","volume":"22","author":"Shanmugasundaram","year":"2022","journal-title":"The Chem Rec"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/nar\/gkad019","article-title":"Versatile strategy using vaccinia virus-capping enzyme to synthesize functional 5' cap-modified mRNAs","volume":"51","author":"Ohno","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1021\/acs.orglett.1c01037","article-title":"Trinucleotide cap analogue bearing a locked nucleic acid moiety: synthesis, mRNA modification, and translation for therapeutic applications","volume":"23","author":"Senthilvelan","year":"2021","journal-title":"Org Lett"},{"key":"B50","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41557-022-00972-7","article-title":"Photocaged 5\u2032 cap analogues for optical control of mRNA translation in cells","volume":"14","author":"Kl\u00f6cker","year":"2022","journal-title":"Nat Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41467-025-58207-5","article-title":"Optochemical control over mRNA translation by photocaged phosphorodiamidate morpholino oligonucleotides in vivo","volume":"16","author":"Tarbashevich","year":"2025","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0968-0004(03)00051-3","article-title":"Regulation of mRNA translation by 5'- and 3'-UTR-binding factors","volume":"28","author":"Wilkie","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","article-title":"Functional 5' UTR mRNA structures in eukaryotic translation regulation and how to find them","volume":"19","author":"Leppek","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/bfgp\/els056","article-title":"Translational control by 3'-UTR-binding proteins","volume":"12","author":"Szostak","year":"2013","journal-title":"Brief Funct Genomics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"a034728","DOI":"10.1101\/cshperspect.a034728","article-title":"What are 3' UTRs doing?","volume":"11","author":"Mayr","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/15476286.2018.1450054","article-title":"Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA","volume":"15","author":"Asrani","year":"2018","journal-title":"RNA Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.omtn.2021.10.007","article-title":"Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2021","journal-title":"Mol Ther - Nucleic Acids"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2019UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Castillo-Hair","year":"2024","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1038\/s41467-021-24436-7","article-title":"High-throughput 5\u2032 UTR engineering for enhanced protein production in non-viral gene therapies","volume":"12","author":"Cao","year":"2021","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-59745-033-1_15","article-title":"In vivo and in vitro analysis of poly(A) length effects on mRNA translation","volume":"419","author":"Peng","year":"2008","journal-title":"Methods In Mol Biology\u2122"},{"key":"B62","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bbrc.2005.03.067","article-title":"Optimized transfection of mRNA transcribed from a d(A\/T)100 tail-containing vector","volume":"330","author":"Elango","year":"2005","journal-title":"Biochem Biophysical Res Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semcdb.2014.05.018","article-title":"Determinants and implications of mRNA poly(A) tail size--does this protein make my tail look big?","volume":"34","author":"Jalkanen","year":"2014","journal-title":"Semin Cell & Developmental Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41580-021-00417-y","article-title":"Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression","volume":"23","author":"Passmore","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ymeth.2017.10.008","article-title":"Design, assembly, production, and transfection of synthetic modified mRNA","volume":"133","author":"Oh","year":"2018","journal-title":"Methods."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e51943","DOI":"10.3791\/51943","article-title":"In vitro synthesis of modified mRNA for induction of protein expression in human cells","author":"Avci-Adali","year":"2014","journal-title":"J visualized experiments : JoVE"},{"key":"B68","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.bbrc.2015.09.102","article-title":"Synthetically modified mRNA for efficient and fast human iPS cell generation and direct transdifferentiation to myoblasts","volume":"473","author":"Preskey","year":"2016","journal-title":"Biochem Biophysical Res Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.cels.2024.05.004","article-title":"Decoupled degradation and translation enables noise modulation by poly(A) tails","volume":"15","author":"Grandi","year":"2024","journal-title":"Cell Syst"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3390\/molecules29112461","article-title":"Effective synthesis of high-integrity mRNA using in vitro transcription","volume":"29","author":"He","year":"2024","journal-title":"Molecules"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.molpharmaceut.2c00010","article-title":"Current status and future perspectives on MRNA drug manufacturing","volume":"19","author":"Webb","year":"2022","journal-title":"Mol Pharmaceutics"},{"key":"B72","volume-title":"Position-specific nucleoside sugar modifications in mRNA ORF: enhancing translational function through complete chemical synthesis of mRNA","author":"Abe","year":"2024"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1021\/acschembio.1c00996","article-title":"Complete chemical synthesis of minimal messenger RNA by efficient chemical capping reaction","volume":"17","author":"Abe","year":"2022","journal-title":"ACS Chem Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1248\/bpb.b22-00746","article-title":"Use of iontophoresis technology for transdermal delivery of a minimal mRNA vaccine as a potential melanoma therapeutic","volume":"46","author":"Husseini","year":"2023","journal-title":"Biol Pharm Bull"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/bit.28684","article-title":"Engineering an Escherichia coli based in vivo mRNA manufacturing platform","volume":"121","author":"Curry","year":"2024","journal-title":"Biotechnol Bioeng"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/app12031543","article-title":"Overview of methods for large-scale RNA synthesis","volume":"12","author":"Ryczek","year":"2022","journal-title":"Appl Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"114961","DOI":"10.1016\/j.addr.2023.114961","article-title":"Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics","volume":"199","author":"Kang","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J pharmaceutics"},{"key":"B80","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.eclinm.2021.100746","article-title":"mRNA vaccines: a matter of delivery","volume":"32","author":"Cao","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.1038\/s41598-023-33941-2","article-title":"Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing","volume":"13","author":"VanderBurgh","year":"2023","journal-title":"Scientific Rep"},{"key":"B84","first-page":"262","article-title":"Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization","volume":"3","author":"Qiu","year":"1996","journal-title":"Gene Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"pdb.prot097261","DOI":"10.1101\/pdb.prot097261","article-title":"Microinjection of mRNAs and oligonucleotides","volume":"2018","author":"Moody","year":"2018","journal-title":"Cold Spring Harb Protoc"},{"key":"B86","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics13030396","article-title":"The ins and outs of messenger RNA electroporation for physical gene delivery in immune cell-based therapy","volume":"13","author":"Campillo-Davo","year":"2021","journal-title":"Pharmaceutics"},{"key":"B87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40290-021-00417-5","article-title":"Delivery strategies for mRNA vaccines","volume":"36","author":"Ramachandran","year":"2022","journal-title":"Pharm Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/nano10020364","article-title":"Nanomedicines to deliver mRNA: state of the art and future perspectives","volume":"10","author":"G\u00f3mez-Aguado","year":"2020","journal-title":"Nanomaterials"},{"key":"B89","first-page":"605","article-title":"Opportunities, barriers, and a strategy for overcoming translational challenges to therapeutic nucleic acid nanotechnology","author":"Afonin","year":"2021","journal-title":"Ther RNA Nanotechnology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"key":"B91","article-title":"Multi-step engineered adeno-associated virus enables whole-brain mRNA delivery","author":"Bai","year":"2024","journal-title":"bioRxiv."},{"key":"B92","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1038\/mtm.2016.57","article-title":"Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR\/Cas9 for efficient gene editing","volume":"3","author":"Park","year":"2016","journal-title":"Mol Ther - Methods & Clin Development"},{"key":"B93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"The Lancet"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4155\/fmc-2022-0027","article-title":"Recent approaches to mRNA vaccine delivery by lipid-based vectors prepared by continuous-flow microfluidic devices","volume":"14","author":"Toudeshkchouei","year":"2022","journal-title":"Future Med Chem"},{"key":"B95","doi-asserted-by":"publisher","first-page":"103505","DOI":"10.1016\/j.drudis.2023.103505","article-title":"Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids","volume":"28","author":"Mendon\u00e7a","year":"2023","journal-title":"Drug Discov Today"},{"key":"B96","doi-asserted-by":"publisher","first-page":"17721","DOI":"10.1021\/acsnano.3c00958","article-title":"Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis","volume":"17","author":"Gao","year":"2023","journal-title":"ACS nano"},{"key":"B97","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.nantod.2014.04.011","article-title":"Intracellular delivery of nanomaterials: how to catch endosomal escape in the act","volume":"9","author":"Martens","year":"2014","journal-title":"Nano Today"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3390\/pharmaceutics12111068","article-title":"The importance of poly (ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles","volume":"12","author":"Zukancic","year":"2020","journal-title":"Pharmaceutics"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1288879","DOI":"10.3389\/fimmu.2023.1288879","article-title":"An mRNA vaccine against rabies provides strong and durable protection in mice","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41541-024-00925-w","article-title":"Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques","volume":"9","author":"Li","year":"2024","journal-title":"npj Vaccin"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2382499","DOI":"10.1080\/21645515.2024.2382499","article-title":"Development of mRNA rabies vaccines","volume":"20","author":"Fang","year":"2024","journal-title":"Hum Vaccin & Immunother"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1099991","DOI":"10.3389\/fimmu.2022.1099991","article-title":"A single vaccination of nucleoside-modified rabies mRNA vaccine induces prolonged highly protective immune responses in mice","volume":"13","author":"Bai","year":"2023","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduction Targeted Therapy"},{"key":"B104","doi-asserted-by":"publisher","first-page":"9368","DOI":"10.1021\/acs.nanolett.4c02440","article-title":"Tailoring highly branched poly (\u03b2-amino ester) s for efficient and Organ-selective mRNA delivery","volume":"24","author":"Yong","year":"2024","journal-title":"Nano Lett"},{"key":"B105","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/cells10010187","article-title":"mRNA-enhanced cell therapy and cardiovascular regeneration","volume":"10","author":"Chanda","year":"2021","journal-title":"Cells"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/pharmaceutics15041106","article-title":"Dendrimer-mediated delivery of DNA and RNA vaccines","volume":"15","author":"Kisakova","year":"2023","journal-title":"Pharmaceutics"},{"key":"B107","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12967-022-03325-7","article-title":"Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications","volume":"20","author":"Amiri","year":"2022","journal-title":"J Translational Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1101\/2020.11.06.371419","volume-title":"Exosome-mediated mRNA delivery for SARS-CoV-2 vaccination","author":"Tsai","year":"2020"},{"key":"B110","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1208\/s12248-016-0015-y","article-title":"Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer","volume":"19","author":"Yang","year":"2017","journal-title":"The AAPS J"},{"key":"B111","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41551-022-00989-w","article-title":"Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy","volume":"7","author":"You","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"B112","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.vesic.2022.100002","article-title":"Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung","volume":"1","author":"Popowski","year":"2022","journal-title":"Extracellular Vesicle"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2015.02.019","article-title":"Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes","volume":"87","author":"Taylor","year":"2015","journal-title":"Methods."},{"key":"B114","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3109\/1547691x.2016.1148089","article-title":"In vitro immunotoxicity assessment of culture-derived extracellular vesicles in human monocytes","volume":"13","author":"Rosas","year":"2016","journal-title":"J immunotoxicology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.molmed.2018.01.006","article-title":"Manufacturing exosomes: a promising therapeutic platform","volume":"24","author":"Colao","year":"2018","journal-title":"Trends Molecular Medicine"},{"key":"B116","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12896-021-00683-w","article-title":"Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope","volume":"21","author":"Aslan","year":"2021","journal-title":"BMC Biotechnol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/biologics4010007","article-title":"Extracellular vesicles: tiny messengers for mighty RNA delivery","volume":"4","author":"Das","year":"2024","journal-title":"Biologics"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e2101224","DOI":"10.1002\/smll.202101224","article-title":"mRNA delivery by a pH-Responsive DNA nano-hydrogel","volume":"17","author":"Fu","year":"2021","journal-title":"Small"},{"key":"B119","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41563-023-01472-w","article-title":"Hydrogels for RNA delivery","volume":"22","author":"Zhong","year":"2023","journal-title":"Nat Mater"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e1800242","DOI":"10.1002\/mabi.201800242","article-title":"Injectable biodegradable chitosan-alginate 3D porous gel scaffold for mRNA vaccine delivery","volume":"19","author":"Yan","year":"2019","journal-title":"Macromolecular Biosci"},{"key":"B121","doi-asserted-by":"publisher","first-page":"102948","DOI":"10.1016\/j.xpro.2024.102948","article-title":"Protocol for delivery of intraoperative immunotherapy to mice by surgical debulking of subcutaneous tumors","volume":"5","author":"Rwandamuriye","year":"2024","journal-title":"STAR Protoc"},{"key":"B122","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.xcrm.2023.101113","article-title":"A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence","volume":"4","author":"Rwandamuriye","year":"2023","journal-title":"Cell Rep Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41587-023-01925-2","article-title":"The global patent landscape of mRNA for diagnosis and therapy","volume":"41","author":"Lyu","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","article-title":"In vivo delivery of nucleic acid-encoded monoclonal antibodies","volume":"34","author":"Patel","year":"2020","journal-title":"BioDrugs"},{"key":"B126","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J Transl Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine Era\u2014mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B129","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: in vitro synthesis of mRNA and its applications in regenerative medicine","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"key":"B130","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13023-019-1177-3","article-title":"Urea cycle disorders in Argentine patients: clinical presentation, biochemical and genetic findings","volume":"14","author":"Silvera-Ruiz","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B131","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jimd.12294","article-title":"Metabolic basis and treatment of citrin deficiency","volume":"44","author":"Hayasaka","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"B132","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ymgme.2019.06.004","article-title":"Current treatment for citrin deficiency during NICCD and adaptation\/compensation stages: strategy to prevent CTLN2","volume":"127","author":"Okano","year":"2019","journal-title":"Mol Genet Metab"},{"key":"B133","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2021.03.004","article-title":"Analysis of daily energy, protein, fat, and carbohydrate intake in citrin-deficient patients: towards prevention of adult-onset type II citrullinemia","volume":"133","author":"Okano","year":"2021","journal-title":"Mol Genet Metab"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.ymthe.2019.04.017","article-title":"mRNA therapy improves metabolic and behavioral abnormalities in a murine model of citrin deficiency","volume":"27","author":"Cao","year":"2019","journal-title":"Mol Ther"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3390\/nu15102284","article-title":"Citrin deficiency: clinical and nutritional features","volume":"15","author":"Komatsu","year":"2023","journal-title":"Nutrients"},{"key":"B136","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.tem.2022.05.002","article-title":"Pathogenic variants of the mitochondrial aspartate\/glutamate carrier causing citrin deficiency","volume":"33","author":"Tavoulari","year":"2022","journal-title":"Trends Endocrinol & Metab"},{"key":"B137","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s100380200046","article-title":"Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD)","volume":"47","author":"Saheki","year":"2002","journal-title":"J Hum Genet"},{"key":"B138","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1152\/ajpregu.00057.2023","article-title":"Loss of hepatic PPAR\u03b1 in mice causes hypertension and cardiovascular disease","volume":"325","author":"Badmus","year":"2023","journal-title":"Am J Physiology-Regulatory, Integr Comp Physiol"},{"key":"B139","volume-title":"Polynucleotides encoding citrin or the treatment of citrullinemia type 2 United States: Modernatx, Inc.","author":"Martini","year":"2023"},{"key":"B140","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s12328-019-01083-6","article-title":"Successful treatment of adult-onset type II citrullinemia with a low-carbohydrate diet and L-arginine after DNA analysis produced a definitive diagnosis","volume":"13","author":"Unita","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/9667","article-title":"The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein","volume":"22","author":"Kobayashi","year":"1999","journal-title":"Nat Genet"},{"key":"B142","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ymgme.2017.02.004","article-title":"Oral aversion to dietary sugar, ethanol and glycerol correlates with alterations in specific hepatic metabolites in a mouse model of human citrin deficiency","volume":"120","author":"Saheki","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2147\/tcrm.s180161","article-title":"Acute intermittent porphyria: current perspectives and case presentation","volume":"15","author":"Spiritos","year":"2019","journal-title":"Ther Clin Risk Management"},{"key":"B144","doi-asserted-by":"publisher","first-page":"e36058","DOI":"10.7759\/cureus.36058","article-title":"Acute intermittent porphyria's symptoms and management: a narrative review","volume":"15","author":"Kizilaslan","year":"2023","journal-title":"Cureus"},{"key":"B145","doi-asserted-by":"publisher","first-page":"17.20.1","DOI":"10.1002\/0471142905.hg1720s86","article-title":"Porphyria diagnostics-part 1: a brief overview of the porphyrias","volume":"86","author":"Ramanujam","year":"2015","journal-title":"Curr Protoc Hum Genet"},{"key":"B146","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/0972-5229.68222","article-title":"Intensive care management of patients with acute intermittent porphyria: clinical report of four cases and review of literature","volume":"14","author":"Mehta","year":"2010","journal-title":"Indian J Crit Care Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/tacg.s48605","article-title":"An update of clinical management of acute intermittent porphyria","volume":"8","author":"Pischik","year":"2015","journal-title":"The Appl Clin Genet"},{"key":"B148","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1373\/clinchem.2005.058198","article-title":"Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion","volume":"52","author":"Floderus","year":"2006","journal-title":"Clin Chem"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e2389","DOI":"10.1002\/brb3.2389","article-title":"Acute porphyrias - a neurological perspective","volume":"11","author":"Gerischer","year":"2021","journal-title":"Brain Behav"},{"key":"B150","doi-asserted-by":"publisher","first-page":"e44260","DOI":"10.7759\/cureus.44260","article-title":"Acute intermittent porphyria: a review and rehabilitation perspective","volume":"15","author":"Valbuena Valecillos","year":"2023","journal-title":"Cureus"},{"key":"B151","doi-asserted-by":"publisher","first-page":"49","DOI":"10.14218\/jerp.2016.00022","article-title":"Pathophysiology, pharmacology and treatment of acute intermittent porphyria: a patient case description and recommendations from the current literature","volume":"2","author":"Ajayi","year":"2017","journal-title":"J Exploratory Res Pharmacol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.gastro.2019.04.050","article-title":"Clinical guide and update on porphyrias","volume":"157","author":"St\u00f6lzel","year":"2019","journal-title":"Gastroenterology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/biomedicines10030648","article-title":"Cutting-edge therapies and novel strategies for acute intermittent porphyria: step-By-step towards the solution","volume":"10","author":"Longo","year":"2022","journal-title":"Biomedicines"},{"key":"B154","unstructured":"Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria United States\n          \n          \n            \n              Martini\n              P\n            \n            \n              Hoge\n              S\n            \n            \n              Benenato\n              K\n            \n            \n              Presnvak\n              V\n            \n            \n              JiangIain\n              L\n            \n          \n          \n          2017"},{"key":"B155","article-title":"Urea cycle enzymes","volume-title":"The online metabolic and molecular bases of inherited disease","author":"Brusilow","year":"2019"},{"key":"B156","article-title":"Citrullinemia type I","volume-title":"GeneReviews(\u00ae). Seattle (WA): University of Washington, Seattle copyright \u00a9 1993-2025, university of Washington, Seattle","author":"Quinonez","year":"2004"},{"key":"B157","article-title":"Rare disease database","author":"Jess","year":"2021","journal-title":"Natl Organ Rare Disord"},{"key":"B158","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7762\/cnr.2021.10.3.268","article-title":"Nutritional management in a patient with citrullinemia type 1","volume":"10","author":"Kang","year":"2021","journal-title":"Clin Nutr Res"},{"key":"B159","volume-title":"mRNA therapy for argininosuccinate synthetase deficiency","author":"Heartlein","year":"2022"},{"key":"B160","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.1375392","article-title":"Cystic fibrosis: molecular biology and therapeutic implications","volume":"256","author":"Collins","year":"1992","journal-title":"Science"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"B162","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/0092-8674(92)90155-6","article-title":"Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)","volume":"68","author":"Bear","year":"1992","journal-title":"Cell"},{"key":"B163","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Anim models Exp Med"},{"key":"B164","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/s0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"The Lancet"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"B166","volume-title":"Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis","author":"Benenato","year":"2019"},{"key":"B167","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/bf01986897","article-title":"Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)","volume":"43","author":"Fabry","year":"1898","journal-title":"Arch F Dermat"},{"key":"B168","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"B169","doi-asserted-by":"publisher","first-page":"5","DOI":"10.47162\/rjme.62.1.01","article-title":"Fabry disease - current data and therapeutic approaches","volume":"62","author":"Ilie-Robert","year":"2021","journal-title":"Rom J Morphol Embryol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J rare Dis"},{"key":"B171","doi-asserted-by":"publisher","first-page":"61415","DOI":"10.18632\/oncotarget.18250","article-title":"Inter-familial and intra-familial phenotypic variability in three Sicilian families with anderson-fabry disease","volume":"8","author":"Tuttolomondo","year":"2017","journal-title":"Oncotarget"},{"key":"B172","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"B173","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","article-title":"Cellular and tissue distribution of intravenously administered agalsidase alfa","volume":"90","author":"Murray","year":"2007","journal-title":"Mol Genet Metab"},{"key":"B174","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for fabry disease","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"B175","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12574-017-0340-x","article-title":"Fabry disease","volume":"15","author":"Yuasa","year":"2017","journal-title":"J Echocardiography."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B177","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology."},{"key":"B178","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J Hum Genet"},{"key":"B179","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and investigational therapeutics for fabry disease","volume":"5","author":"Felis","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B180","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"The Am J Hum Genet"},{"key":"B181","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3978\/j.issn.2224-4336.2015.10.07","article-title":"Phenylketonuria: a review of current and future treatments","volume":"4","author":"Al Hafid","year":"2015","journal-title":"Translational Pediatr"},{"key":"B182","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat Rev Dis primers"},{"key":"B183","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/9780470122808.ch6","article-title":"The phenylalanine hydroxylating system from mammalian liver","volume":"35","author":"Kaufman","year":"1971","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41436-018-0081-x","article-title":"Allelic phenotype values: a model for genotype-based phenotype prediction in phenylketonuria","volume":"21","author":"Garbade","year":"2019","journal-title":"Genet Med"},{"key":"B185","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/j.1536-4801.2001.tb07453.x","article-title":"Intake and blood levels of fatty acids in treated patients with phenylketonuria","volume":"33","author":"Acosta","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/s0002-8223(03)00983-0","article-title":"Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy","volume":"103","author":"Acosta","year":"2003","journal-title":"J Am Diet Assoc"},{"key":"B187","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.gim.0000117335.50541.f3","article-title":"Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors","volume":"6","author":"Acosta","year":"2004","journal-title":"Genet Med"},{"key":"B188","article-title":"mRNA therapy for phenylketonuria","author":"Frank","year":"2022"},{"key":"B189","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B190","doi-asserted-by":"publisher","first-page":"15856","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging"},{"key":"B191","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.3390\/molecules26237223","article-title":"Pharmacological chaperone therapy for pompe disease","volume":"26","author":"Borie-Guichot","year":"2021","journal-title":"Molecules"},{"key":"B192","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr Treat Options Neurol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"292","DOI":"10.21037\/atm.2019.05.29","article-title":"Pompe disease: what are we missing?","volume":"7","author":"Schoser","year":"2019","journal-title":"Ann Transl Med"},{"key":"B194","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23934","article-title":"GAA variants and phenotypes among 1,079 patients with pompe disease: data from the pompe registry","volume":"40","author":"Reuser","year":"2019","journal-title":"Hum Mutat"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s12035-019-01820-5","article-title":"Molecular approaches for the treatment of pompe disease","volume":"57","author":"Bellotti","year":"2020","journal-title":"Mol Neurobiol"},{"key":"B196","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur J Hum Genet"},{"key":"B197","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/(sici)1096-8628(19980827)79:1<69::aid-ajmg16>3.0.co;2-k","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am J Med Genet"},{"key":"B198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci112262","article-title":"Trafficking of lysosomal enzymes in normal and disease states","volume":"77","author":"Kornfeld","year":"1986","journal-title":"J Clin Invest"},{"key":"B199","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J Biol Chem"},{"key":"B200","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/s0140-6736(08)61555-x","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"The Lancet"},{"key":"B202","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"key":"B203","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"B204","volume-title":"mRNA therapy for pompe disease","author":"Frank DeRosa","year":"2023"},{"key":"B205","volume-title":"A Phase 3b, Open-label, safety and immunogenicity study of SARS-CoV-2 mRNA-1273 vaccine in adult solid organ transplant recipients and healthy controls","year":"2021"},{"key":"B206","volume-title":"A phase 3, randomized, observer-blind study to evaluate the safety, tolerability, and immunogenicity of multiple formulations of the vaccine candidate bnt162b2 against covid 19 in healthy adults 18 through 55 years of age 2021","year":"2021"},{"key":"B207","volume-title":"Safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy subjects: a phase I, randomized, placebo-controlled, observer-blind study 2020","year":"2020"},{"key":"B208","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nat Med"},{"key":"B209","volume-title":"A Global, Multi-center, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine in population aged 18 years and older","year":"2021"},{"key":"B210","volume-title":"A Phase 2 Randomized, Observer-blind, placebo-controlled study to assess the safety, reactogenicity, and immunogenicity of the SARS CoV-2 vaccine ARCT-021 in healthy adult participants","year":"2020"},{"key":"B211","volume-title":"Immunogenicity and safety of the first-in-human SARS-CoV-2 mRNA vaccine formulation in healthy adults 18 years of age and older","year":"2021"},{"key":"B212","volume-title":"A phase 1\/2, dose-finding study to evaluate safety, tolerability, and immunogenicity of the ChulaCov19 vaccine in healthy adults","year":"2020"},{"key":"B213","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/s41598-023-49653-6","article-title":"Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study","volume":"14","author":"Puthanakit","year":"2024","journal-title":"Scientific Rep"},{"key":"B214","volume-title":"Phase I safety and immunogenicity trial of an investigational RNActive\u00ae rabies vaccine (CV7201) in healthy adults","year":"2014"},{"key":"B215","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/s0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"The Lancet"},{"key":"B216","volume-title":"A Non-Randomized, Open label, controlled, dose-escalation, phase I clinical trial to evaluate the safety, reactogenicity and immunogenicity of one or two administrations of candidate rabies mRNA vaccine CV7202 in healthy adult subjects","year":"2018"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"B218","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"key":"B219","article-title":"Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine","volume-title":"Healthy adults: final results from a phase 1\/2 randomized trial","author":"Ananworanich","year":"2024"},{"key":"B220","volume-title":"Phase 1\/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1020 and mRNA-1030 candidate seasonal influenza vaccines in healthy adults","year":"2022"},{"key":"B221","volume-title":"A phase 2a randomized, observer-blind, dose-finding study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older","year":"2024"},{"key":"B222","volume-title":"A phase 1\/2, randomized, dose-Finding\/dose-confirmation study to evaluate the reactogenicity, safety and immunogenicity of mRNA-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults","year":"2023"},{"key":"B223","volume-title":"A phase 1, randomized, placebo-controlled, dose ranging study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-1944, encoding for an anti-chikungunya virus monoclonal antibody, in healthy adults","year":"2019"},{"key":"B224","volume-title":"A phase 1, randomized, open-label clinical trial to evaluate the safety and immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV trimer mRNA vaccines in healthy, HIV-uninfected adult participants","year":"2021"},{"key":"B225","volume-title":"A phase 1, randomized, first-in-human, open-label study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA vaccine (mRNA-1644) and Core-g28v2 60mer mRNA vaccine (mRNA-1644v2-Core) in HIV-1 uninfected adults in good general health","year":"2021"},{"key":"B226","volume-title":"A phase 1 clinical trial to evaluate the safety and immunogenicity of ferritin nanoparticles expressing native-like HIV-1 envelope trimers followed by boost with mRNA lipid nanoparticles encoding a native-like HIV-1 envelope trimer in adults without HIV","year":"2023"},{"key":"B227","first-page":"e450","volume-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","author":"Lorentzen","year":"2022"},{"key":"B228","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","article-title":"Safety and immunogenicity of a messenger RNA\u2013based cytomegalovirus vaccine in healthy adults: results from a phase 1 randomized clinical trial","volume":"230","author":"Fierro","year":"2024","journal-title":"The J Infect Dis"},{"key":"B229","volume-title":"A phase 1, randomized, observer-blind, placebo-controlled, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of cytomegalovirus vaccines mRNA-1647 and mRNA-1443 when administered to healthy adults","year":"2017"},{"key":"B230","volume-title":"A phase 1\/2, randomized, observer-blind, active-controlled, dose-ranging study to evaluate the safety, reactogenicity and immunogenicity of mRNA-1468, a candidate vaccine to prevent herpes zoster (HZ) in healthy adults \u226550 years of age","year":"2023"},{"key":"B231","volume-title":"A phase 1\/2 randomized, observer-blind study to evaluate the safety, tolerability, and immunogenicity of a modified rna vaccine against Varicella zoster virus in healthy individual","year":"2023"},{"key":"B232","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac206","article-title":"Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults","volume-title":"Open forum infectious diseases","author":"August","year":"2022"},{"key":"B233","volume-title":"A phase 1, randomized, observer-blind, placebo-controlled, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, when administered to healthy adults","year":"2018"},{"key":"B234","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","article-title":"A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases","volume":"69","author":"Jansen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B235","article-title":"Randomized controlled phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III\/IV melanoma patients who are disease-free following the local treatment of macrometastases","year":"2012"},{"key":"B236","doi-asserted-by":"publisher","first-page":"e70020","DOI":"10.1002\/ctm2.70020","article-title":"NY\u2010ESO\u20101 antigen: a promising frontier in cancer immunotherapy","volume":"14","author":"Alsalloum","year":"2024","journal-title":"Clin Translational Med"},{"key":"B237","article-title":"Open-label, randomized phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with Anti-PD-1-refractory\/Relapsed, unresectable stage III or IV melanoma","year":"2020"},{"key":"B238","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.1016\/j.annonc.2020.08.209","article-title":"88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo) adjuvant patients with triple negative breast cancer","volume":"31","author":"Schmidt","year":"2020","journal-title":"Ann Oncol"},{"key":"B239","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"key":"B240","volume-title":"A phase 1\/2 study of combination immunotherapy and mRNA vaccine in subjects with non-small cell lung cancer (NSCLC)","year":"2017"},{"key":"B241","doi-asserted-by":"publisher","first-page":"14679","DOI":"10.3390\/ijms241914679","article-title":"Cancer\/testis antigens as targets for RNA-based anticancer therapy","volume":"24","author":"Shim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B242","volume-title":"A phase 1, open-label, multicenter study to assess the safety and tolerability of mRNA-5671\/V941 as a monotherapy and in combination with pembrolizumab in participants with KRAS mutant advanced or metastatic non-small cell lung cancer, colorectal cancer or pancreatic adenocarcinoma","year":"2019"},{"key":"B243","volume-title":"A multi-site, open-label, phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, stage II (high risk) and stage III colorectal cancer patients who are ctDNA positive following resection","year":"2020"},{"key":"B244","doi-asserted-by":"publisher","first-page":"e20200389","DOI":"10.1084\/jem.20200389","article-title":"Profiling HPV-16\u2013specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients","volume":"217","author":"Bhatt","year":"2020","journal-title":"J Exp Med"},{"key":"B245","volume-title":"An open label phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1","year":"2020"},{"key":"B246","doi-asserted-by":"publisher","first-page":"e433330","DOI":"10.1200\/edbk_433330","article-title":"Breaking ground in recurrent or metastatic head and neck squamous cell carcinoma: novel therapies beyond PD-L1 immunotherapy","volume":"44","author":"Rosenberg","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B247","doi-asserted-by":"publisher","first-page":"S1404","DOI":"10.1016\/j.annonc.2022.08.035","article-title":"LBA38 BNT211-01: a phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours","volume":"33","author":"Mackensen","year":"2022","journal-title":"Ann Oncol"},{"key":"B248","volume-title":"Phase I\/IIa, first-in-human (FIH), open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors","year":"2020"},{"key":"B249","doi-asserted-by":"publisher","first-page":"A1754","DOI":"10.1136\/jitc-2023-sitc2023.1530","article-title":"1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab","author":"Gainor","year":"2023","journal-title":"Late-Breaking Abstr"},{"key":"B250","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/jco.2019.37.15_suppl.2523","article-title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors","volume":"37","author":"Burris","year":"2019","journal-title":"J Clin Oncol"},{"key":"B251","volume-title":"A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors","year":"2017"},{"key":"B252","volume-title":"A phase 3, randomized, double-blind, Placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with high-risk stage II-IV melanoma (INTerpath-001)","year":"2023"},{"key":"B253","volume-title":"A phase 3, randomized, double-blind, Placebo- and active-comparator-controlled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with resected stage II, IIIA, IIIB (N2) non-small cell lung cancer (INTerpath-002)","year":"2023"},{"key":"B254","volume-title":"Phase 1 clinical trial of personalized neoantigen tumor vaccines and programmed death-ligand 1 (PD-L1) blockade in patients with surgically resected pancreatic cancer","year":"2019"},{"key":"B255","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B256","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2643","volume-title":"Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer","author":"Cafri","year":"2019"},{"key":"B257","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/jci134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J Clin Invest"},{"key":"B258","volume-title":"A global, phase 1\/2, open label, dose escalation study to evaluate the safety, pharmacodynamics, and pharmacokinetics of mRNA-3704 in patients with isolated methylmalonic acidemia due to Methylmalonyl-CoA mutase deficiency","year":"2019"},{"key":"B259","volume-title":"A global, phase 1\/2, open-label, dose optimization study to evaluate the safety, pharmacodynamics, and pharmacokinetics of mRNA-3927 in participants with propionic acidemia","year":"2019"},{"key":"B260","volume-title":"Phase 2, randomized, double-blind, placebo-controlled, nested single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ARCT-810 in adolescent and adult participants with ornithine transcarbamylase deficiency","year":"2022"},{"key":"B261","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/biomedicines11082227","article-title":"Genetic therapy approaches for ornithine transcarbamylase deficiency","volume":"11","author":"Seker Yilmaz","year":"2023","journal-title":"Biomedicines"},{"key":"B262","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1038\/s41467-024-51056-8","article-title":"Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy","volume":"15","author":"Bai","year":"2024","journal-title":"Nat Commun"},{"key":"B263","volume-title":"A phase 1\/2 dose escalation study evaluating the safety, and tolerability and efficacy of VX-522 in subjects 18 years of age and older with cystic fibrosis and a CFTR genotype not responsive to CFTR modulator therapy","year":"2022"},{"key":"B264","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"B265","volume-title":"A phase 1\/2, randomized, double-blinded, placebo-controlled, combined single and multiple ascending dose study evaluating the safety, tolerability, and biological activity of MRT5005 administered by nebulization to adult subjects with cystic fibrosis","year":"2017"},{"key":"B266","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41467-019-08852-4","article-title":"Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes","volume":"10","author":"Gan","year":"2019","journal-title":"Nat Commun"},{"key":"B267","volume-title":"A phase I, randomized, single-blind, placebo controlled study to assess the safety, tolerability and pharmacodynamics of AZD8601 after single dose administration to Male patients with type II diabetes mellitus (T2DM)","year":"2016"},{"key":"B268","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41573-021-00355-6","article-title":"VEGFA mRNA for regenerative treatment of heart failure","volume":"21","author":"Coll\u00e9n","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B269","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol Ther"},{"key":"B270","volume-title":"A randomized, double-blind, placebo-controlled, multi-centre, sequential design, phase IIa study to evaluate safety and tolerability of epicardial injections of AZD8601 during coronary artery bypass grafting surgery","year":"2017"},{"key":"B271","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/nejmoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"New Engl J Med"},{"key":"B272","volume-title":"Phase 1 two-part (Open-label, single ascending dose (part 1) and open-label, single dose expansion (part 2)) study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and patients with transthyretin amyloidosis-related cardiomyopathy (ATTR-CM)","year":"2020"},{"key":"B273","volume-title":"MAGNITUDE: a phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of NTLA-2001 in participants with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)","year":"2023"},{"key":"B274","doi-asserted-by":"crossref","unstructured":"Analysis of off-target effects and risk assessment leading from preclinical to clinical trials of gene-edited therapeutic products\n          \n          538\n          51\n          10.1007\/s43441-022-00481-2\n          Ther Innovation & Regul Sci\n          57\n          2023","DOI":"10.1007\/s43441-022-00481-2"},{"key":"B275","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2021.06.020","article-title":"Synthetic modified messenger RNA for therapeutic applications","volume":"131","author":"Gao","year":"2021","journal-title":"Acta Biomater"},{"key":"B276","doi-asserted-by":"publisher","first-page":"17509","DOI":"10.1038\/s41598-018-35570-6","article-title":"Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing","volume":"8","author":"Sun","year":"2018","journal-title":"Scientific Rep"},{"key":"B277","doi-asserted-by":"publisher","first-page":"122565","DOI":"10.1016\/j.ijpharm.2022.122565","article-title":"Efficient delivery of VEGF-A mRNA for promoting diabetic wound healing via ionizable lipid nanoparticles","volume":"632","author":"Zha","year":"2023","journal-title":"Int J Pharmaceutics"},{"key":"B278","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","article-title":"Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial","volume":"18","author":"Anttila","year":"2020","journal-title":"Mol Ther - Methods & Clin Development"},{"key":"B279","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"Zhou","year":"2010","journal-title":"Science"},{"key":"B280","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat Commun"},{"key":"B281","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41564-023-01325-x","article-title":"Molecular characterization of human cytomegalovirus infection with single-cell transcriptomics","volume":"8","author":"Schwartz","year":"2023","journal-title":"Nat Microbiol"},{"key":"B282","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13643-022-02004-4","article-title":"Prevalence, incidence, and risk factors associated with cytomegalovirus infection in healthcare and childcare worker: a systematic review and meta-analysis","volume":"11","author":"Balegamire","year":"2022","journal-title":"Syst Rev"},{"key":"B283","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/0264-410x(91)90187-b","article-title":"High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity","volume":"9","author":"G\u00f6ncz\u00f6l","year":"1991","journal-title":"Vaccine"},{"key":"B284","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1016\/j.vaccine.2015.10.078","article-title":"A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells","volume":"33","author":"McVoy","year":"2015","journal-title":"Vaccine"},{"key":"B285","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/tropicalmed7120439","article-title":"Challenges, recent advances and perspectives in the treatment of human cytomegalovirus infections","volume":"7","author":"Chen","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"B286","article-title":"Inventors; ModernaTX, inc. Cambridge (US), assignee. Human cytomegalovirus RNA vaccines","volume":"11","author":"Ciaramella","year":"2022","journal-title":"United States patent US"},{"key":"B287","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1186\/s12889-022-13971-7","article-title":"A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development","volume":"22","author":"Fowler","year":"2022","journal-title":"BMC Public Health"},{"key":"B288","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/1471-0528.17966","article-title":"Congenital cytomegalovirus infection: update on screening, diagnosis and treatment: scientific impact paper no. 56","volume":"132","author":"Khalil","year":"2025","journal-title":"BJOG: Int J Obstet Gynaecol"},{"key":"B289","doi-asserted-by":"publisher","first-page":"eabm2536","DOI":"10.1126\/sciadv.abm2536","article-title":"Structural basis for HCMV pentamer receptor recognition and antibody neutralization","volume":"8","author":"Kschonsak","year":"2022","journal-title":"Sci Adv"},{"key":"B290","volume-title":"Infectious disease vaccines United States: ModernaTX, Inc.","author":"Ciaramella","year":"2022"},{"key":"B291","doi-asserted-by":"publisher","first-page":"2450045","DOI":"10.1080\/21645515.2025.2450045","article-title":"The mRNA-1647 vaccine: a promising step toward the prevention of cytomegalovirus infection (CMV)","volume":"21","author":"Akingbola","year":"2025","journal-title":"Hum Vaccin & Immunother"},{"key":"B292","article-title":"A study to evaluate the efficacy, safety, and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in allogenic hematopoietic cell transplantation (HCT) participants","author":"ModernaTX","year":"2025","journal-title":"NIH.Gov: ClinicalTrials.gov ID NCT05683457"},{"key":"B293","doi-asserted-by":"publisher","first-page":"107365","DOI":"10.1016\/j.intimp.2021.107365","article-title":"An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses","volume":"92","author":"Rahimi","year":"2021","journal-title":"Int Immunopharmacology"},{"key":"B294","volume-title":"BetaCoronavirus mRNA vaccine United States: modernatx","author":"Ciaramella","year":"2021"},{"key":"B295","doi-asserted-by":"publisher","first-page":"112240","DOI":"10.1016\/j.envres.2021.112240","article-title":"The global transmission of new coronavirus variants","volume":"206","author":"Zhao","year":"2022","journal-title":"Environ Res"},{"key":"B296","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/AP-200220-0772","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B297","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/molecules26051446","article-title":"Structure-based virtual screening identifies multiple stable binding sites at the RecA domains of SARS-CoV-2 helicase enzyme","volume":"26","author":"Ahmad","year":"2021","journal-title":"Molecules"},{"key":"B298","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jaccas.2020.04.027","article-title":"Sex differences in mortality from COVID-19 pandemic: are men vulnerable and women protected?","volume":"2","author":"Sharma","year":"2020","journal-title":"JACC: Case Rep"},{"key":"B299","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B300","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/nejmp2000929","article-title":"A novel coronavirus emerging in China\u2014Key questions for impact assessment","volume":"382","author":"Munster","year":"2020","journal-title":"New Engl J Med"},{"key":"B301","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-022-05522-2","article-title":"The WHO estimates of excess mortality associated with the COVID-19 pandemic","volume":"613","author":"Msemburi","year":"2023","journal-title":"Nature"},{"key":"B302","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","article-title":"Lassa fever\u2014the road ahead","volume":"21","author":"Garry","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B303","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/10408360490497456","article-title":"Lassa virus","volume":"41","author":"G\u00fcnther","year":"2004","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B304","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jhep.2022.06.031","article-title":"Exotic viral hepatitis; a review on epidemiology, pathogenesis, and treatment","volume":"77","author":"van Leeuwen","year":"2022","journal-title":"J Hepatol"},{"key":"B305","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coviro.2018.05.002","article-title":"Lassa virus glycoprotein: stopping a moving target","volume":"31","author":"Hastie","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B306","doi-asserted-by":"publisher","first-page":"10768","DOI":"10.1128\/jvi.00941-08","article-title":"Identification of a broad-spectrum arenavirus entry inhibitor","volume":"82","author":"Larson","year":"2008","journal-title":"J Virol"},{"key":"B307","article-title":"Lassa virus vaccine Germany","author":"Jasny","year":"2023","journal-title":"CureVac AG T\u00fcbingen (DE)"},{"key":"B308","volume-title":"Cancer vaccines United States: ModernaTX, inc. Cambridge","author":"Valiante","year":"2016"},{"key":"B309","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1097\/jto.0000000000000334","article-title":"The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer","volume":"9","author":"Rami-Porta","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-19-8937-7_1","article-title":"Epidemiology, detection and management of cancer: an overview","volume-title":"Deep learning in cancer diagnostics: a feature-based transfer learning evaluation","author":"Arzmi","year":"2023"},{"key":"B311","first-page":"239","volume-title":"Composition and vaccine for treating lung cancer Germany: Curevac AG t\u00fcbingen (DE)","author":"Kallen","year":"2021"},{"key":"B312","volume-title":"RNA cancer vaccines United States: modernatx","author":"Ashburn","year":""},{"key":"B313","volume-title":"RNA cancer vaccines United States: ModernaTX, inc. Cambridge","author":"Valiante","year":"2019"},{"key":"B314","volume-title":"Personalized cancer vaccine epitope selection United States of America: modernatx, Inc","author":"Zhong","year":"2020"},{"key":"B315","article-title":"mRNA based gene expression for personalizing patient cancer therapy with an mdm2 antagonist Switzerland","author":"Chen","year":"2015","journal-title":"F Hoffmann-la Roche Ag"},{"key":"B316","volume-title":"Composition and vaccine for treating prostate cancer Germany: Curevac AG T\u00fcbingen DE","author":"Kallen","year":"2016"},{"key":"B317","volume-title":"Messenger ribonucleic acids for enhancing immune responses and methods of use thereof United States: ModernaTX, Inc.","author":"Huang","year":"2020"},{"key":"B318","volume-title":"Methods and compositions for treating cancer using mRNA therapeutics United States: ModernaTX, Inc.","author":"Frederick","year":"2023"},{"key":"B319","volume-title":"mRNA combination therapy for the treatment of cancer United States: ModernaTX, inc. Cambridge","author":"Frederick","year":"2023"}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10784\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:28:28Z","timestamp":1767864508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2025.10784\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":319,"alternative-id":["10.3389\/ebm.2025.10784"],"URL":"https:\/\/doi.org\/10.3389\/ebm.2025.10784","relation":{},"ISSN":["1535-3699"],"issn-type":[{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"10784"}}